Literature DB >> 11384787

Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data.

A R Willan1.   

Abstract

Stinnett and Mullahy recently introduced the concept of net health benefit as an alternative to cost-effectiveness ratios for the statistical analysis of patient-level data on the costs and health effects of competing interventions. Net health benefit addresses a number of problems associated with cost-effectiveness ratios by assuming a value for the willingness-to-pay for a unit of effectiveness. We extend the concept of net health benefit to demonstrate that standard statistical procedures can be used for the analysis, power, and sample size determinations of cost-effectiveness data. We also show that by varying the value of the willingness-to-pay, the point estimate and confidence interval for the incremental cost-effectiveness ratio can be determined. An example is provided.

Entities:  

Mesh:

Year:  2001        PMID: 11384787     DOI: 10.1016/s0197-2456(01)00110-6

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  12 in total

Review 1.  Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Authors:  Niklas Zethraeus; Magnus Johannesson; Bengt Jönsson; Mickael Löthgren; Magnus Tambour
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 2.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

3.  Cognitive behavioral therapy for insomnia in stable heart failure: Protocol for a randomized controlled trial.

Authors:  Nancy S Redeker; Andrea K Knies; Christopher Hollenbeak; H Klar Yaggi; John Cline; Laura Andrews; Daniel Jacoby; Anna Sullivan; Meghan O'Connell; Joanne Iennaco; Lisa Finoia; Sangchoon Jeon
Journal:  Contemp Clin Trials       Date:  2017-01-31       Impact factor: 2.226

4.  Sample size and power for cost-effectiveness analysis (part 1).

Authors:  Henry A Glick
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

5.  Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care.

Authors:  David Wonderling; Andrew J Vickers; Richard Grieve; Rob McCarney
Journal:  BMJ       Date:  2004-03-15

6.  Cost-utility analysis of a dance intervention for adolescent girls with internalizing problems.

Authors:  Anna Philipsson; Anna Duberg; Margareta Möller; Lars Hagberg
Journal:  Cost Eff Resour Alloc       Date:  2013-02-20

7.  Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals of asthma treatment.

Authors:  Persijn J Honkoop; Rik J B Loymans; Evelien H Termeer; Jiska B Snoeck-Stroband; Moira J Bakker; Willem J J Assendelft; Peter J Sterk; Gerben Ter Riet; Tjard R J Schermer; Jacob K Sont
Journal:  BMC Pulm Med       Date:  2011-11-24       Impact factor: 3.317

8.  Joint distribution approaches to simultaneously quantifying benefit and risk.

Authors:  Michele L Shaffer; Kristi L Watterberg
Journal:  BMC Med Res Methodol       Date:  2006-10-12       Impact factor: 4.615

9.  Study protocol randomised controlled trial comparison of cost-utility and cost-effectiveness of a face-to-face rehabilitation programme versus a telemedicine programme in the treatment of patients with chronic low back pain.

Authors:  Adelaida M Castro-Sanchez; Guillermo Adolfo Matarán-Peñarrocha; Silvia Gómez-García; Héctor García-López; Lazaro Andronis; Manuel Albornoz-Cabello; Inmaculada C Lara Palomo
Journal:  BMJ Open       Date:  2020-12-12       Impact factor: 2.692

10.  Comparison of the effectiveness of an e-health program versus a home rehabilitation program in patients with chronic low back pain: A double blind randomized controlled trial.

Authors:  Inmaculada Carmen Lara-Palomo; Eduardo Antequera-Soler; Guillermo A Matarán-Peñarrocha; Manuel Fernández-Sánchez; Héctor García-López; Adelaida María Castro-Sánchez; María Encarnación Aguilar-Ferrándiz
Journal:  Digit Health       Date:  2022-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.